Actualités

Boston Scientific stock has fallen about 50% over the past year, yet valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach both suggest the shares may be trading below what the fundamentals imply. That gap between weak recent returns and an undervalued read is now front of mind for anyone looking at the current US$51.83 share price. Over the last 12 months, Boston Scientific has declined 49.8%, which puts recent investor sentiment and the current...

Boston Scientific (NYSE: BSX) has initiated multiple product recalls covering cardiac ablation generators and vascular access sheaths due to labeling discrepancies and air embolism risks. The recalls affect a broad mix of devices used in cardiac and vascular procedures across several international markets. Regulators and hospitals are assessing the implications for device safety protocols, clinical workflows, and future use of the impacted products. Product safety questions can prompt...

Boston Scientific's 2026 guidance cut tests its recovery as WATCHMAN weakness, EP share losses and delayed margin gains push a broader rebound toward 2028.

Boston Scientific recently reported its second-quarter 2026 results, showing sales of US$5,442 million and net income of US$907 million, alongside issuing a recall of its Rapid Refill Continuous Injection System and initiating a multi-year global restructuring plan aimed at cost efficiencies. While the company raised full-year 2026 net sales growth expectations to approximately 5.5%–6.5%, it also outlined a restructuring program costing up to US$800 million and targeting around US$500...

Boston Scientific (BSX) lowered its full-year guidance below Wall Street's estimates on Wednesday, c

Boston Scientific logged higher second-quarter results and cut its full-year outlook as it begins a new restructuring plan announced earlier this week.

Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.5% year on year to $5.44 billion. On the other hand, next quarter’s revenue guidance of $5.27 billion was less impressive, coming in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.86 per share was 3.8% above analysts’ consensus estimates.

Boston expects its restructuring plan to cost between $700m and $800m and be completed by the end of 2029.

Boston Scientific stock has had a tough run over the past year, yet the valuation checks still lean supportive, setting up a clear tension between recent share price weakness and what the broader metrics suggest about value. Boston Scientific shares are down about 58.1% over the past year, which sharply resets expectations around what investors are willing to pay for the business. Upcoming earnings and progress integrating recent device acquisitions may support sentiment, while ongoing Class...

Recall driven attention on Boston Scientific stock Boston Scientific (BSX) is back in focus after a series of voluntary recalls for its CRE and CRE Pro Wireguided gastrointestinal devices, tied to potential sterile pouch breaches across widely distributed product lots. With more than 81,000 units cited in individual recall notices and a worldwide distribution footprint, the situation brings product quality controls, potential regulatory implications and timing before the upcoming earnings...

JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.

SpaceX, IBM and Boston Scientific fell to 52-week lows on Wednesday as Wall Street concerns and profit-taking sent the stocks lower.

Boston Scientific recently initiated several voluntary Class II recalls of its CRE and CRE Pro Wireguided endoscopy devices worldwide due to potential sterile breaches in packaging, affecting tens of thousands of units across multiple size ranges. The recalls underscore the operational and regulatory risks inherent in Boston Scientific’s expanding minimally invasive device portfolio, especially as it integrates recent acquisitions and scales global distribution. We’ll now examine how these...

In the latest trading session, Boston Scientific (BSX) closed at $42.63, marking a -4.52% move from the previous day.

Boston Scientific stock has fallen 56.5% over the past year, yet the valuation checks still lean toward the shares looking cheap relative to fundamentals and recent news has put a fresh spotlight on whether that gap is justified. The 56.5% one year share price decline raises the question of whether Boston Scientific is being priced for a much weaker outlook than its long term potential would suggest. On one side, the US$1.5b investment in MiRus and option to acquire its TAVR business may...

Boston Scientific Corporation (NYSE:BSX) is one of the most promising future stocks to buy right now. Stifel cut the price target on Boston Scientific Corporation (NYSE:BSX) to $65 from $75 on June 25 and reaffirmed a Buy rating on the shares. The rating update came after the firm hosted five deep left atrial appendage closure […]

In the most recent trading session, Boston Scientific (BSX) closed at $42.68, indicating a -1.84% shift from the previous trading day.

In the most recent trading session, Boston Scientific (BSX) closed at $44.46, indicating a -2.5% shift from the previous trading day.

Earlier in June 2026, the US Food and Drug Administration posted a Class II, firm-initiated recall of 9,750 Boston Scientific Orca sterile, single-use air/water and suction valves (lot 38400303, expiring January 20, 2029) after higher-than-expected reports of suction buttons sticking during gastrointestinal endoscopy procedures. The recall, which is ongoing and affects nationwide US distribution, highlights how even accessory devices can create operational and regulatory pressures for a...

Boston Scientific (NYSE:BSX) has initiated a nationwide recall of its Orca Single Use Air/Water and Suction Valves. The recall is voluntary and follows identification of a device malfunction affecting procedures across the United States. The action reflects a material operational event for the company, with implications for patient safety oversight. Boston Scientific is a major medical device company, so a recall tied to endoscopy accessories like the Orca Single Use Air/Water and Suction...

While the market fixates on a disruptive quarter for Stryker stock, the company's powerful ability to convert profit into hard cash reveals a deeper, under-appreciated resilience.

Boston Scientific Corporation (NYSE:BSX) is one of the most promising healthcare stocks according to Wall Street analysts. On June 4, Truist Securities lowered its price target on Boston Scientific Corporation (NYSE:BSX) from $85 to $64, while keeping its Buy rating on the stock. Richard Newitter, the analyst on record, cited a growing slowdown in demand […]

Boston Scientific (BSX) closed the most recent trading day at $44.95, moving 4.2% from the previous trading session.

Adobe, Chewy, and Boston Scientific fell to 52-week lows on Friday after receiving multiple price target cuts from Wall Street analysts.

Boston Scientific has considerably underperformed its sector peers recently, yet analysts remain highly optimistic about the stock’s prospects.

Boston Scientific was down about 0.7% at close, while Lowe's Companies ended the session 3% lower, and Conagra Brands fell by about 1.3%.

Boston Scientific Corporation (NYSE:BSX) is among the 10 Most Oversold S&P 500 Stocks So Far in 2026. On May 29, Wolfe Research downgraded the stock from Outperform to Peer Perform. This marks the end of the firm’s bullish outlook on the stock for four years, with the adjustment coming after the company said sales growth […]

Medtronic has underperformed the Nasdaq Composite, and analysts remain somewhat optimistic about the stock’s outlook.

Analyst downgrades, weak outlooks, and management changes added pressure.

Investing.com -- Wolfe Research downgraded Boston Scientific to Peer Perform in a note on Friday, declaring the end of a multiyear bullish thesis on the medical device company after its two key growth engines (pulsed field ablation and the Watchman left atrial appendage closure device) stalled sharply in the first half of 2026.